ArticleEuropean journal of haematology2025
Gender Disparities in Health-Related Quality of Life in Patients With Chronic Lymphocytic Leukemia: Impact of Treatment Modality.
Article in European journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gender Disparities in Health-Related Quality of Life in Patients With Chronic Lymphocytic Leukemia: Impact of Treatment Modality.European journal of haematology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In chronic lymphocytic leukemia (CLL), treatment initiation is deferred until clinical symptoms emerge, aiming to minimize treatment-related burden and maintain health-related quality-of-life (QoL). We examined gender differences in QoL among patients undergoing active surveillance versus targeted therapies. Participants completed the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) Questionnaire, and the score was derived from the FACT-General (FACT-G) and leukemia-specific concerns (Leu-Subscale). Comparisons between treatment groups were conducted using Student's t-test, stratified by sex. Among 210 participants, 63 were under surveillance, 115 in treatment, and 32 post-treatment. Among men, the surveillance group reported better physical well-being (mean: 25.2 vs. 19.7, p < 0.001), Leu-Subscale (mean: 51.5 vs. 42.8, p = 0.002), and FACT-Leu (mean: 135.9 vs. 120.5, p = 0.02) compared to the active treatment group. In contrast, women in surveillance reported lower social well-being (mean: 18.9 vs. 22.5, p = 0.008); emotional well-being (mean: 15.5 vs. 18.2, p = 0.003); FACT-G (mean: 74.6 vs. 83.3, p = 0.009); and FACT-Leu (mean: 116.7 vs. 128.3, p = 0.014) compared to the active treatment. A significant interaction was observed between treatment group and sex in the emotional well-being subscale. In conclusion, men in surveillance reported better overall QoL than those in active treatment, whereas women in active treatment experienced better overall QoL than those in surveillance. These findings highlight the importance of gender-specific approaches to improve health-related QoL in CLL care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.